SRSD-216

N/A

Report date: 2025/09/16 20:00:07
NME

Base Information

Drug NameSRSD-216
Drug Alias NameSRSD216SRSD-216
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceApolipoprotein(a) modulators
TargetsApolipoprotein(a)
Therapy Area/IndicationsHyperlipoproteinemiasCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSirius Therapeutics Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSirius Therapeutics Co LtdSirius Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHyperlipoproteinemiasCardiovascular Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A